Syneos Health at ASH 2026

Hematology development demands decisions that connect emerging science with the realities of clinical care. From selecting comparators in a changing treatment landscape to planning biomarker strategies and delivering complex therapies, each choice shapes what comes next for your program.

Meet with Syneos Health at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition to discuss your development priorities. Our medical, scientific and operational specialists bring experience across leukemia, lymphoma and multiple myeloma, supporting programs from first-in-human studies through global execution.

Turn Your Science Into a Development Strategy

• Agility That Scales: Build a development approach around your science, modality and stage. Our experience includes the Beat AML® Master Clinical Trial, which uses rapid genomic profiling to match patients to targeted treatment approaches within an evolving study framework.
• Medical Expertise at Every Milestone: Work with hematology specialists who bring a drug development perspective to protocol strategy, safety oversight and study delivery. Discuss questions around dose optimization, biomarker selection and complex modalities, including bispecific antibodies and antibody-drug conjugates.
• Proactive Guidance for Trial Decisions: Anticipate patient and site challenges before they affect study delivery. We combine therapeutic expertise with data and AI-enabled protocol intelligence to inform feasibility, recruitment planning and approaches that support continued participation.
• Commercial Thinking from the Start: Consider how clinical decisions support future differentiation, value and access. Our teams connect development strategy with commercial insights to help sponsors plan for the evidence needs of patients, clinicians and healthcare decision-makers.

Perspectives to Inform Your Next Decision

Precision Medicine in Practice: The Beat AML Master Clinical Trial
See how a master clinical trial model brings genomic profiling and targeted treatment approaches together in acute myeloid leukemia.
Read the Case Study

Choosing the Right Comparator in Multiple Myeloma
Consider how evolving treatment standards influence comparator selection and development strategy across early- and late-phase studies.
Download the White Paper

Executing MRD in Oncology Trials
Hear Syneos Health experts and special guests from Natera discuss measurable residual disease (MRD), from trial design and regulatory positioning to commercial considerations.
Watch the On-Demand Webinar